Using extraordinary powers under Para 19 of DPCO 2013 is not a substitute for a permanent pricing framework. Critically analyse.

Para 19 of the Drugs (Prices Control) Order, 2013 lets the NPPA fix prices "in public interest" in extraordinary circumstances. It is currently the only legal basis for Trade Margin Rationalisation (TMR) [2]. The latest use caps margins on 137 non-scheduled anti-cancer drugs, with revised MRPs for 543 brands from 9 November 2026 [1]. Para 19 works as a precise emergency tool, but it cannot stand in for a permanent framework.

Why Para 19 has been useful

• Reaches beyond ceiling prices: about 82% of the market by value is non-scheduled, so ceiling prices do not cover it [2]. Para 19 lets NPPA act on this segment selectively.
• Large price cuts: Bevacizumab 100 mg falls from ₹21,767.70 to ₹5,930.13 [1]. In the 2019 pilot (42 drugs), MRPs fell by up to 90% [3], saving patients about ₹984 crore a year [2].
• Quick response in a crisis: it was used to cap prices of coronary stents (2017) and COVID-era devices (2021) [2].
• Narrow targeting: only about 4% of the non-scheduled market has markups above 100% of the distributor price [2]. Targeted action spares cheap, viable generics.

Why it is not enough

• Weak legal footing: Para 19 is an extraordinary, time-limited power. DPCO has no permanent provision for TMR. The 33rd Standing Committee Report called the delay "inordinate", and the Department says it has "no set time frame" [2].
• Uncertainty from case-by-case action: MSME pharma associations object to the "span and extent" of TMR [2]. Firms cannot predict which drug will be targeted next.
• Only the trade margin is cut: NPPA has no cost-audit power [2]. As a result, the factory price of patented biologics sold by a single company is never examined.
• Weak enforcement: stock is still sold at pre-revised MRPs, overcharging demands total ₹10,013.30 crore, and 15 of 48 NPPA posts are vacant [2].

Way forward

• Write TMR into DPCO 2013 within a set deadline, with margins that fall in percentage terms as drug prices rise.
• Allow cost-based pricing where markups are abnormally high, and set up fast-track dispute settlement [2].

Para 19 has shown that capping margins works, but it is an emergency tool and cannot replace a stable rulebook. A permanent, consultative TMR framework, as the Standing Committee recommended, would give patients lasting affordability, give industry predictability, and move India towards SDG 3.8 (universal health coverage).